Search

Your search keyword '"Ou Yen‐Chuan"' showing total 899 results
Start Over Author "Ou Yen‐Chuan"
899 results on '"Ou Yen‐Chuan"'

102. Significant predictors of contralateral upper tract recurrence after radical nephroureterectomy for upper tract urothelial carcinoma

Author

Chen, Chuan‐Shu, primary, Li, Jian‐Ri, additional, Yang, Cheng‐Kuang, additional, Cheng, Chen‐Li, additional, Yang, Chi‐Rei, additional, Ou, Yen‐Chuan, additional, Ho, Hao‐Chung, additional, Lin, Chia‐Yen, additional, Hung, Sheng‐Chun, additional, Chen, Cheng‐Che, additional, Wang, Shu‐Chi, additional, and Wang, Shian‐Shiang, additional

Published
2021
Full Text
View/download PDF

110. MP53-16 ONCOLOGIC OUTCOMES IN MEN WITH METASTASIS TO THE PROSTATIC ANTERIOR FAT PAD LYMPH NODES: A MULTI-INSTITUTION INTERNATIONAL STUDY

Author

Kim, Isaac, Ha, Yun-Sok, Modi, Parth, Salmasi, Amirali, Parihar, Jaspreet, Patel, Neal, Faiena, Izak, May, Michael, Lee, Daivd, Llukani, Elton, Patrick, Tuliao, Rha, Koon Ho, Ahlering, Thomas, Skarecky, Douglas, Ahn, Hanjong, Choi, Seung-Kwon, Park, Sejun, Jeon, Seong Soo, Ou, Yen-Chuan, Eun, Daniel, Manucha, Varsha, Albala, David, Badani, Ketan, Yuh, Bertram, Ruel, Nora, Kwon, Tae Gyun, Marchalik, Daniel, Hwang, Jonathan, and Kim, Wun-Jae

Published
2015
Full Text
View/download PDF

113. Evaluation of an artificial intelligence algorithm for assisting the Paris System in reporting urinary cytology: A pilot study.

Author

Ou, Yen‐Chuan, Tsao, Tang‐Yi, Chang, Ming‐Chen, Lin, Yi‐Sheng, Yang, Wei‐Lei, Hang, Jen‐Fan, Li, Chi‐Bin, Lee, Ching‐Ming, Yeh, Cheng‐Hung, and Liu, Tien‐Jen

Abstract

Background: The Paris System for Reporting Urinary Cytology (TPS) has been shown to improve bladder cancer diagnosis. Advances in artificial intelligence (AI) may assist and improve the clinical workflow by applying TPS in routine diagnostic services. Methods: A deep‐learning–based algorithm was developed to identify urothelial cancer candidate cells using whole‐slide images (WSIs). In the testing cohort, 131 urine cytology slides were retrospectively retrieved and analyzed using this AI algorithm. The authors compared the performance of one cytopathologist and two cytotechnologists using AI‐assisted digital urine cytology. Then, the AI‐assisted WSIs were evaluated in the clinical workflow. The cytopathologist first made a diagnosis by reviewing the AI‐inferred WSIs and quantitative data (nuclear‐to‐cytoplasmic ratio and nuclear size) for each sample. After a washout period, the same cytopathologist made a diagnosis for the same samples using direct microscopy. All diagnosis results were compared with the expert panel consensus. Results: The AI‐assisted diagnosis by the two cytotechnologists and the one cytopathologist demonstrated performance results that were comparable to the expert panel consensus (sensitivity, 79.5% and 82.1% vs. 92.3%, respectively; specificity, 100% and 98.9% vs. 100%, respectively). Furthermore, the performance of the AI‐assisted WSIs compared with the microscopic diagnosis by the cytopathologist demonstrated superior sensitivity (92.3% vs. 87.2%) and negative predictive value (96.8% vs. 94.8%). In addition, the AI‐assisted reporting demonstrated near perfect agreement with the expert panel consensus (κ = 0.944) and the microscopic diagnosis (κ = 0.862). Conclusions: The AI algorithm developed by the authors effectively assisted TPS‐based reporting by providing AI‐inferred WSIs and quantitative data. A deep‐learning–based algorithm was developed to assist the Paris System‐based urine cytology reporting using whole‐slice imaging with automatic annotation of urothelial cells at risk and quantitative information, such as nuclear‐to‐cytoplasmic ratios. Compared with conventional microscopic examination, the algorithm‐assisted method displayed superior sensitivity (87.2% vs. 92.3%), better negative predictive value (94.8% vs. 96.8%), and nearly perfect agreement with the expert panel consensus (k = 0.862). [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

120. Phloretin Ameliorates Testosterone-Induced Benign Prostatic Hyperplasia in Rats by Regulating the Inflammatory Response, Oxidative Stress and Apoptosis

Author

Hsu, Chao Yu, Lin, Yi Sheng, Weng, Wei Chun, Panny, Lauren, Chen, Hsiang Lai, Tung, Min Che, Ou, Yen Chuan, Lin, Chi Chien, Yang, Che Hsueh, Hsu, Chao Yu, Lin, Yi Sheng, Weng, Wei Chun, Panny, Lauren, Chen, Hsiang Lai, Tung, Min Che, Ou, Yen Chuan, Lin, Chi Chien, and Yang, Che Hsueh

Abstract

The inflammatory process is proposed to be one of the factors to benign prostatic enlargement (BPH), and this is the first study examining the anti-inflammatory ability of phloretin in treating rats with testosterone-induced BPH. BPH would be induced by testosterone (10 mg/kg/day testosterone subcutaneously for 28 days), and the other groups of rats were treated with phloretin 50 mg/kg/day or 100 mg/kg/day orally (phr50 or phr100 group) after induction. Prostate weight and prostate weight to body weight ratio were significantly reduced in the Phr100 group. Reduced dihydrotestosterone without interfering with 5α-reductase was observed in the phr100 group. In inflammatory proteins, reduced IL-6, IL-8, IL-17, NF-κB, and COX-2 were seen in the phr100 group. In reactive oxygen species, malondialdehyde was reduced, and superoxide dismutase and glutathione peroxidase were elevated in the phr100 group. In apoptotic assessment, elevated cleaved caspase-3 was observed in rats of the phr100 group. Enhanced pro-apoptotic Bax and reduced anti-apoptotic Bc1-2 could be seen in the phr100 group. In histological stains, markedly decreased glandular hyperplasia and proliferative cell nuclear antigen were observed with reduced expression in the phr100 group. Meanwhile, positive cells of terminal deoxynucleotidyl transferase dUTP nick end labeling were increased in the phr100 group. In conclusion, the treatment of phloretin 100 mg/kg/day could ameliorate testosterone-induced BPH.

Published
2021
Full Text
View/download PDF

122. Graptopetalum paraguayense E. Walther leaf extracts protect against brain injury in ischemic rats

Author

Kao, Tsung-Kuei, Ou, Yen-Chuan, Raung, Shue-Ling, Chen, Wen-Ying, Yen, Yu-Ju, Lai, Ching-Yi, Chou, Su-Tze, and Chen, Chun-Jung

Subjects
Materia medica, Vegetable -- Usage, Materia medica, Vegetable -- Health aspects, Materia medica, Vegetable -- Research, Plant extracts -- Usage, Plant extracts -- Health aspects, Plant extracts -- Research, Animal experimentation -- Usage, Ischemia -- Care and treatment, Brain -- Injuries, Brain -- Care and treatment, Health
Published
2010

125. An open-label, pharmacokinetic study to determine the bioavailability, safety and tolerability of single dose oral docetaxel in metastatic prostate cancer (mPC) patients treated with IV docetaxel.

Author

Jackson, Christopher G. C. A., primary, Ou, Yen-chuan, additional, En, Meng, additional, Chao, Tsu-Yi, additional, Hung, Noelyn Anne, additional, Wang, David, additional, Cutler, David, additional, Kramer, Douglas, additional, Zhi, Jay, additional, Chan, Wing Kai, additional, Kwan, Min-Fun Rudolf, additional, and Hung, Tak, additional

Published
2021
Full Text
View/download PDF

128. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial.

Author

UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - (SLuc) Unité d'oncologie médicale, UCL - (SLuc) Centre du cancer, Petrylak, Daniel P, de Wit, Ronald, Chi, Kim N, Drakaki, Alexandra, Sternberg, Cora N, Nishiyama, Hiroyuki, Castellano, Daniel, Hussain, Syed A, Fléchon, Aude, Bamias, Aristotelis, Yu, Evan Y, van der Heijden, Michiel S, Matsubara, Nobuaki, Alekseev, Boris, Necchi, Andrea, Géczi, Lajos, Ou, Yen-Chuan, Coskun, Hasan Senol, Su, Wen-Pin, Bedke, Jens, Gakis, Georgios, Percent, Ivor J, Lee, Jae-Lyun, Tucci, Marcello, Semenov, Andrey, Laestadius, Fredrik, Peer, Avivit, Tortora, Giampaolo, Safina, Sufia, Garcia Del Muro, Xavier, Rodriguez-Vida, Alejo, Cicin, Irfan, Harputluoglu, Hakan, Tagawa, Scott T, Vaishampayan, Ulka, Aragon-Ching, Jeanny B, Hamid, Oday, Liepa, Astra M, Wijayawardana, Sameera, Russo, Francesca, Walgren, Richard A, Zimmermann, Annamaria H, Hozak, Rebecca R, Bell-McGuinn, Katherine M, Powles, Thomas, Machiels, Jean-Pascal, UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - (SLuc) Unité d'oncologie médicale, UCL - (SLuc) Centre du cancer, Petrylak, Daniel P, de Wit, Ronald, Chi, Kim N, Drakaki, Alexandra, Sternberg, Cora N, Nishiyama, Hiroyuki, Castellano, Daniel, Hussain, Syed A, Fléchon, Aude, Bamias, Aristotelis, Yu, Evan Y, van der Heijden, Michiel S, Matsubara, Nobuaki, Alekseev, Boris, Necchi, Andrea, Géczi, Lajos, Ou, Yen-Chuan, Coskun, Hasan Senol, Su, Wen-Pin, Bedke, Jens, Gakis, Georgios, Percent, Ivor J, Lee, Jae-Lyun, Tucci, Marcello, Semenov, Andrey, Laestadius, Fredrik, Peer, Avivit, Tortora, Giampaolo, Safina, Sufia, Garcia Del Muro, Xavier, Rodriguez-Vida, Alejo, Cicin, Irfan, Harputluoglu, Hakan, Tagawa, Scott T, Vaishampayan, Ulka, Aragon-Ching, Jeanny B, Hamid, Oday, Liepa, Astra M, Wijayawardana, Sameera, Russo, Francesca, Walgren, Richard A, Zimmermann, Annamaria H, Hozak, Rebecca R, Bell-McGuinn, Katherine M, Powles, Thomas, and Machiels, Jean-Pascal

Abstract

Ramucirumab-an IgG1 vascular endothelial growth factor receptor 2 antagonist-plus docetaxel was previously reported to improve progression-free survival in platinum-refractory, advanced urothelial carcinoma. Here, we report the secondary endpoint of overall survival results for the RANGE trial. We did a randomised, double-blind, phase 3 trial in patients with advanced or metastatic urothelial carcinoma who progressed during or after platinum-based chemotherapy. Patients were enrolled from 124 investigative sites (hospitals, clinics, and academic centres) in 23 countries. Previous treatment with one immune checkpoint inhibitor was permitted. Patients were randomly assigned (1:1) using an interactive web response system to receive intravenous ramucirumab 10 mg/kg or placebo 10 mg/kg volume equivalent followed by intravenous docetaxel 75 mg/m (60 mg/m in Korea, Taiwan, and Japan) on day 1 of a 21-day cycle. Treatment continued until disease progression, unacceptable toxicity, or other discontinuation criteria were met. Randomisation was stratified by geographical region, Eastern Cooperative Oncology Group performance status at baseline, and visceral metastasis. Progression-free survival (the primary endpoint) and overall survival (a key secondary endpoint) were assessed in the intention-to-treat population. The study is registered with ClinicalTrials.gov, NCT02426125; patient enrolment is complete and the last patient on treatment is being followed up for safety issues. Between July 20, 2015, and April 4, 2017, 530 patients were randomly allocated to ramucirumab plus docetaxel (n=263) or placebo plus docetaxel (n=267) and comprised the intention-to-treat population. At database lock (March 21, 2018) for the final overall survival analysis, median follow-up was 7·4 months (IQR 3·5-13·9). In our sensitivity analysis of investigator-assessed progression-free survival at the overall survival database lock, median progression-free survival remained significantly improved wi

Published
2020

129. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE):a randomised, open-label, multicentre, phase 3 trial

Author

Powles, Thomas, Van Der Heijden, Michiel S., Castellano, Daniel, Galsky, Matthew D, Loriot, Yohann, Petrylak, Daniel P, Ogawa, Osamu, Park, Se Hoon, Lee, Jae-lyun, De Giorgi, Ugo, Bögemann, Martin, Bamias, Aristotelis, Eigl, Bernhard J, Gurney, Howard, Mukherjee, Som D, Fradet, Yves, Skoneczna, Iwona, Tsiatas, Marinos, Novikov, Andrey, Suárez, Cristina, Fay, André P, Duran, Ignacio, Necchi, Andrea, Wildsmith, Sophie, He, Philip, Angra, Natasha, Gupta, Ashok K, Levin, Wendy, Bellmunt, Joaquim, Lee, Jae Lyun, Eigl, Bernhard J., Mukherjee, Som D., Suarez, Cristina, Westgeest, Hans, Flechon, Aude, Ou, Yen-chuan, Pappot, Helle, Sengelov, Lisa, Powles, Thomas, Van Der Heijden, Michiel S., Castellano, Daniel, Galsky, Matthew D, Loriot, Yohann, Petrylak, Daniel P, Ogawa, Osamu, Park, Se Hoon, Lee, Jae-lyun, De Giorgi, Ugo, Bögemann, Martin, Bamias, Aristotelis, Eigl, Bernhard J, Gurney, Howard, Mukherjee, Som D, Fradet, Yves, Skoneczna, Iwona, Tsiatas, Marinos, Novikov, Andrey, Suárez, Cristina, Fay, André P, Duran, Ignacio, Necchi, Andrea, Wildsmith, Sophie, He, Philip, Angra, Natasha, Gupta, Ashok K, Levin, Wendy, Bellmunt, Joaquim, Lee, Jae Lyun, Eigl, Bernhard J., Mukherjee, Som D., Suarez, Cristina, Westgeest, Hans, Flechon, Aude, Ou, Yen-chuan, Pappot, Helle, and Sengelov, Lisa

Published
2020

136. Geriatric Nutritional Risk Index as a Prognostic Marker for Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Docetaxel

Author

Chang, Li-Wen, primary, Hung, Sheng-Chun, additional, Li, Jian-Ri, additional, Chiu, Kun-Yuan, additional, Yang, Cheng-Kuang, additional, Chen, Chuan-Shu, additional, Lu, Kevin, additional, Chen, Cheng-Che, additional, Wang, Shu-Chi, additional, Lin, Chia-Yen, additional, Cheng, Chen-Li, additional, Ou, Yen-Chuan, additional, Yang, Shun-Fa, additional, Hsu, Chiann-Yi, additional, Ho, Szu-Hang, additional, and Wang, Shian-Shiang, additional

Published
2021
Full Text
View/download PDF

137. Docetaxel Rechallenge Improves Survival in Patients With Metastatic Castration-resistant Prostate Cancer: A Retrospective Study

Author

HUNG, SHENG-CHUN, primary, CHANG, LI-WEN, additional, LI, JIAN-RI, additional, WANG, SHIAN-SHIANG, additional, YANG, CHENG-KUANG, additional, CHEN, CHUAN-SHU, additional, LU, KEVIN, additional, CHEN, CHENG-CHE, additional, WANG, SHU-CHI, additional, LIN, CHIA-YEN, additional, CHENG, CHEN-LI, additional, OU, YEN-CHUAN, additional, and CHIU, KUN-YUAN, additional

Published
2021
Full Text
View/download PDF

138. Pelvic lymph node dissection using indocyanine green fluorescence lymphangiography in robotic assisted radical prostatectomy for non-lymph node or distant metastasis prostate cancer patients

Author

Chuang, Yu-Feng, primary, Ou, Yen-Chuan, additional, Lin, Yi-Sheng, additional, Huang, Li-Hua, additional, Weng, Wei-Chun, additional, Chang, Yu-Kang, additional, Chen, Hung-Lin, additional, Hsu, Chao-Yu, additional, Tung, Min-Che, additional, and Lu, Chin-Heng, additional

Published
2021
Full Text
View/download PDF

141. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

Author

Powles, Thomas, primary, van der Heijden, Michiel S, additional, Castellano, Daniel, additional, Galsky, Matthew D, additional, Loriot, Yohann, additional, Petrylak, Daniel P, additional, Ogawa, Osamu, additional, Park, Se Hoon, additional, Lee, Jae-Lyun, additional, De Giorgi, Ugo, additional, Bögemann, Martin, additional, Bamias, Aristotelis, additional, Eigl, Bernhard J, additional, Gurney, Howard, additional, Mukherjee, Som D, additional, Fradet, Yves, additional, Skoneczna, Iwona, additional, Tsiatas, Marinos, additional, Novikov, Andrey, additional, Suárez, Cristina, additional, Fay, André P, additional, Duran, Ignacio, additional, Necchi, Andrea, additional, Wildsmith, Sophie, additional, He, Philip, additional, Angra, Natasha, additional, Gupta, Ashok K, additional, Levin, Wendy, additional, Bellmunt, Joaquim, additional, van der Heijden, Michiel S., additional, Lee, Jae Lyun, additional, Eigl, Bernhard J., additional, Powles, Thomas, additional, Mukherjee, Som D., additional, Suarez, Cristina, additional, Westgeest, Hans, additional, Flechon, Aude, additional, Ou, Yen-Chuan, additional, Park, Inkeun, additional, Matveev, Vsevolod, additional, Pérez-Valderrama, Begoña, additional, Cheng, Susanna, additional, Frank, Stephen, additional, Anido, Urbano, additional, Hamzaj, Alketa, additional, Retz, Margitta, additional, Sridhar, Srikala, additional, Scagliotti, Giorgio Vittorio, additional, Voortman, Jens, additional, Alekseev, Boris, additional, Alyasova, Anna, additional, Komyakov, Boris, additional, Dumez, Herlinde, additional, Pavic, Michel, additional, Kimura, Go, additional, Mizokami, Atsushi, additional, Osanto, Susanne, additional, Arranz, Jose Angel, additional, Piersma, Djura, additional, Shin, Sang Joon, additional, Karyakin, Oleg, additional, Delgado, Ignacio, additional, Gonzalez, Jose Luis, additional, Pang, See-Tong, additional, Tran, Anna, additional, Lipatov, Oleg, additional, Su, Wen-Pin, additional, Flaig, Thomas, additional, Alva, Ajjai, additional, Park Kyong, Hwa, additional, Kopyltsov, Evgeny, additional, Almagro, Elena, additional, Domenech, Monserrat, additional, Chang, Yen-Hwa, additional, Sautois, Brieuc, additional, Ravaux, Andre, additional, Aravantinos, Gerasimos, additional, Georgoulias, Vasileios, additional, Mulder, Sasja, additional, Kim, Yu Jung, additional, Kater, Fabio, additional, Chevreau, Christine, additional, Tagawa, Scott, additional, Zalewski, Pawel, additional, Joly, Florence, additional, Hatiboglu, Gencay, additional, Gianni, Luca, additional, Morelli, Franco, additional, Tambaro, Rosa, additional, Hashimoto, Yasuhiro, additional, Nosov, Alexander, additional, Font, Albert, additional, Rodriguez-Vida, Alejo M., additional, Jones, Robert, additional, Vasudev, Naveen, additional, Srinivas, Sandhya, additional, Zhang, Jingsong, additional, Gil, Thierry, additional, Finch, Daygen, additional, Grimm, Marc-Oliver, additional, Su, Yu-Li, additional, Chowdhury, Simon, additional, Hocking, Christopher, additional, Plas, Eugen, additional, North, Scott, additional, Jensen, Niels Viggo, additional, Theodore, Christine, additional, Imkamp, Florian, additional, Peer, Avivit, additional, Kobayashi, Takashi, additional, Sakai, Hideki, additional, Sassa, Naoto, additional, Yoshimura, Kazuhiro, additional, Aarts, Maureen, additional, Ferreira Castro, Ana, additional, Topuzov, Marlen, additional, Rodriguez, Juan Francisco, additional, Vazquez, Federico Jose, additional, Tsai, Yu-Chieh, additional, Crabb, Simon, additional, Hussain, Syed, additional, Bendell, Johanna, additional, Gross-Goupil, Marine, additional, Gwenaelle, Gravis, additional, Berger, Raanan, additional, Statsenko, Galina, additional, Evans, Linda, additional, Drakaki, Alexandra, additional, Somer, Bradley, additional, Davis, Ian, additional, Lynam, James, additional, Borges, Giuliano, additional, Dettino, Aldo, additional, Fay, André P., additional, Martins, Graziella, additional, Zucca, Luis Eduardo, additional, Agerbaek, Mads, additional, Kalofonos, Haralambos, additional, Rosenbaum, Eli, additional, Enokida, Hideki, additional, Kikukawa, Hiroaki, additional, Nishimura, Kazuo, additional, Tamada, Satoshi, additional, Uemura, Motohide, additional, Lopez, Yamil, additional, Gietema, Jourik, additional, Slojewski, Marcin, additional, Fernandes, Isabel, additional, Smolin, Alexey, additional, Mazhar, Danish, additional, Kalebasty, Arash Rezazadeh, additional, Carthon, Bradley, additional, Loidl, Wolfgang, additional, Franke, Fabio, additional, Girotto, Gustavo, additional, Alimohamed, Nimira, additional, Macfarlane, Robyn, additional, Pappot, Helle, additional, Niegisch, Guenter, additional, Mavroudis, Dimitrios, additional, Sella, Avishay, additional, Porta, Camillo, additional, Ebara, Shin, additional, Nakamura, Motonobu, additional, Obara, Wataru, additional, Okuno, Norihiko, additional, Shinohara, Nobuo, additional, Sugimoto, Mikio, additional, Suzuki, Akitaka, additional, Tokuda, Noriaki, additional, Uemura, Hiroji, additional, Yamaguchi, Akito, additional, Ramirez, Francisco, additional, Rozanowski, Pawel, additional, Wiechno, Pawel, additional, Keam, Bhumsuk, additional, Kislov, Nikolay, additional, Plaksin, Denis, additional, Cicin, Irfan, additional, Kumar, Satish, additional, Galsky, Matthew D., additional, Petrylak, Daniel P., additional, Rosales, Joseph, additional, Vaishampayan, Ulka, additional, Culine, Stephane, additional, Papandreou, Christos, additional, Nara, Taketoshi, additional, Erman, Mustafa, additional, Kreiger, Laurence, additional, Janoski, Juliana, additional, Rosa, Diogo, additional, Siqueira, Mariana, additional, Canil, Christina, additional, Sengelov, Lisa, additional, Tourani, Jean-Marc, additional, Arai, Gaku, additional, Hashine, Katsuyoshi, additional, Kawakita, Mutsushi, additional, Nakaigawa, Noboru, additional, Nomi, Hayahito, additional, Shiina, Hiroaki, additional, Suzuki, Hiroyoshi, additional, Yonese, Junji, additional, Kuri, Roberto, additional, Macedo, Eleazar, additional, Rivera, Samuel, additional, Villalobos Prieto, Alberto, additional, Polakiewicz-Gilowska, Anna, additional, Zaucha, Renata, additional, Lopes, Fabio, additional, Ponomarev, Roman, additional, Pomerantz, Mark, additional, Shariat, Shahrokh, additional, Luk, Cynthia, additional, and Lesniewski-Kmak, Krzysztof, additional

Published
2020
Full Text
View/download PDF

144. Detailed Analysis of Patients with Metastasis to the Prostatic Anterior Fat Pad Lymph Nodes: A Multi-Institutional Study

Author

Kim, Isaac Yi, Modi, Parth K., Sadimin, Evita, Ha, Yun-Sok, Kim, Jeong Hyun, Skarecky, Douglas, Cha, Doh Yoon, Wambi, Chris O., Ou, Yen-Chuan, Yuh, Bertram, Park, Sejun, Llukani, Elton, Albala, David M., Wilson, Timothy, Ahlering, Thomas, Badani, Ketan, Ahn, Hanjong, Lee, David I., May, Michael, Kim, Wun-Jae, and Lee, Dong Hyeon

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results